Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Posted inClinical Updates news OB/GYN & Women's Health

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.
Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
Posted innews OB/GYN & Women's Health

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.
Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis
Posted innews OB/GYN & Women's Health Oncology

Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis

The VENUSCANCER secondary analysis of 275,792 records from 103 population-based registries reveals wide global variation in stage at diagnosis, concordance with guideline-recommended initial treatments, and time to treatment for breast, cervical, and ovarian cancers — with consistent shortfalls in early detection in LMICs and marked intercountry variability in care.
Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results
Posted innews OB/GYN & Women's Health Public Health

Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results

A multifaceted national preterm birth prevention programme in Australia was associated with a modest national decrease in late preterm births and, after a hospital collaborative, a substantial reduction in early‑term births in participating centres, without increasing preterm rates.